v3.25.1
Segment Reporting
3 Months Ended
Mar. 31, 2025
Segment Reporting  
Segment Reporting

Note 16. Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The CODM is the Company’s Chief Executive Officer.

“Adjusted EBITDA,” which is defined by the Company as earnings before interest, income taxes, depreciation, amortization and certain items that do not contribute directly to management’s evaluation of its operating results, is the profit measure used by the CODM for each operating segment in measuring the performance of the business and in the annual budget and forecasting process. Asset information by reportable segment is not provided to the CODM.

We have two operating segments that are aggregated under our Life Sciences Services segment, which provides temperature-controlled logistics and cryogenic biostorage within the life science industry through direct sales. Revenues from this segment include an immaterial amount of product revenues. The Company’s Life Sciences Products segment manufactures and sells cryogenic freezers, cryogenic dewars and accessories within the life science industry through direct sales or a distribution network. Revenues from this reportable segment are exclusively life sciences product revenues.

In addition, the CODM manages and evaluates the operating performance of the segments, as described above, on a precorporate cost allocation basis.  Accordingly, for segment reporting purposes, the Company does not allocate corporate costs, which include certain aspects of the Company’s executive management, legal, compliance, human resources, information technology and finance departments, to its reportable segments.  

Information about our segments is as follows (in thousands):

Three Months Ended March 31, 2025

Three Months Ended March 31, 2024

    

Life Sciences Services

    

Life Sciences Products

    

Total

    

Life Sciences Services

    

Life Sciences Products

    

Total

    

Revenue from external customers 1

$

23,213

$

17,827

$

41,040

$

19,874

$

17,417

$

37,291

Intersegment revenue

 

245

 

150

 

395

 

83

 

174

 

257

23,458

17,977

41,435

19,957

17,591

37,548

Reconciliation of revenue

Elimination of intersegment revenue

(395)

(257)

Total consolidated revenue

41,040

37,291

Less:

Cost of revenue 1, 2

6,660

7,333

5,851

7,971

Employee related expenses

13,051

5,435

12,558

5,488

Engineering and development expense 3

983

412

1,468

434

Rent

1,803

187

1,337

190

Other segment items 4

3,445

1,100

3,683

1,385

Adjusted EBITDA for reportable segments

$

(2,484)

$

3,510

$

1,026

$

(4,940)

$

2,123

$

(2,817)

Corporate overhead costs

(3,845)

(3,840)

Depreciation and amortization expense

(6,134)

(5,747)

Acquisition and integration costs

(1)

(60)

Divestiture costs

(2,290)

-

Cost reduction initiatives

(216)

-

Investment income

1,573

2,600

Unrealized (gain)/loss on investments

(193)

1,737

Foreign currency (gain)/loss

(245)

(563)

Interest expense, net

(583)

(1,275)

Change in fair value of contingent consideration

5,178

(293)

Stock-based compensation expense

(3,064)

(4,666)

Income taxes

(234)

(111)

Loss from continuing operations

$

(9,028)

$

(15,035)

(1) Life Sciences Services segment includes immaterial revenue from external customers and cost of revenue associated with life sciences products revenue and cost of products revenue, respectively.

(2) Cost of revenue is exclusive of employee related expenses of $6.9 million and $6.7 million, depreciation and amortization of $2.0 million and $1.9 million, stock-based compensation of $0.6 million and $0.7 million, and rent of $0.8 million and $0.6 million for the three months ended March 31, 2025 and 2024, respectively.

(3) Engineering and development expense is exclusive of employee related expenses of $2.3 million and $2.3 million, stock-based compensation of $0.2 million and $0.4 million, and depreciation and amortization of $0.1 million and $0.1 million for the three months ended March 31, 2025 and 2024, respectively.

(4) Other segment items primarily includes professional services, facility allocations, dues and subscriptions, audit fees, insurance, legal fees, and travel expense.